iO’s population genomic screening program enables proactive and preventative healthcare by identifying increased risk for hereditary cancers and heart disease.

iO’s population genomic screening program enables proactive and preventative healthcare by identifying increased risk for hereditary cancers and heart disease.

We have developed a first of its kind, fully-digital population health pilot program that integrates clinical genomics into standard care as part of Ochsner’s focus on delivering personalized healthcare.

The population genomic screening program proactively tests patients to identify those who are at higher risk for certain hereditary cancers and heart disease. Early detection of a genetic variant and intervention in accordance with well-established, evidence-based clinical guidelines can significantly reduce risks of disease and potentially prevent future illness.

Through our partnership with Color, we combine clinical-grade genomic sequencing, clinical services, and patient engagement with our approach to making individualized patient-level insights actionable and integrating them into our electronic health record, so population genomic information can be used in routine patient care at scale.

The program has been highlighted by MedCity News and FierceHealthcare, among others.